Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent

Andrew H. Murr, Timothy Smith, Peter H. Hwang, Neil Bhattacharyya, Brent J. Lanier, James W. Stambaugh, Andrew S. Mugglin

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background: Inflammation/polyp recurrence, adhesions, and middle turbinate lateralization are causes of suboptimal outcomes following sinus surgery and lead to increased rates of revision. A bioabsorbable, drug-eluting stent was evaluated for its ability to preserve sinus patency by providing controlled steroid delivery to the sinus mucosa. The study objective was to assess safety and efficacy of a steroid-eluting sinus stent when used following functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis (CRS). Methods: Prospective, multicenter, randomized, double-blind clinical trial, enrolling 43 patients in 2 groups. One group (n = 38) used an intrapatient control design comparing drug-eluting to non-drug-eluting stents. The other group (n = 5) received bilateral drug-eluting stents to assess systemic safety. Endoscopic follow-up was performed for 60 days. Efficacy endpoints included assessment of inflammation, polyp formation, adhesions, and middle turbinate position. Results: Stents were successfully deployed in all 86 sinuses. Compared to the control stent, the drug-eluting stent provided statistically significant reduction in inflammation at days 21 to 45 (p <0.003), frequency of polyp formation (p = 0.0391), and frequency of significant adhesion (p = 0.0313). Reduced frequency of middle turbinate lateralization was also apparent though not statistically significant. No device-related adverse events occurred. Eluted steroid was unquantifiable systemically and there was no evidence of adrenal cortical suppression. Conclusion: This study demonstrates the safety and efficacy of a novel bioabsorbable, steroid-eluting stent for use in CRS patients. The steroid-eluting stent is effective in improving wound healing by preserving sinus patency, reducing inflammation, and minimizing adhesions via controlled local steroid delivery without measurable systemic exposure.

Original languageEnglish (US)
Pages (from-to)23-32
Number of pages10
JournalInternational Forum of Allergy and Rhinology
Volume1
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Stents
Steroids
Safety
Turbinates
Drug-Eluting Stents
Polyps
Inflammation
Drug Design
Wound Healing
Mucous Membrane
Clinical Trials
Recurrence
Equipment and Supplies

Keywords

  • Bioabsorbable
  • Corticosteroid
  • FESS
  • Functional endoscopic sinus surgery
  • Inflammation
  • Sinusitis
  • Stent
  • Steroid-eluting
  • Turbinate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology
  • Medicine(all)

Cite this

Murr, A. H., Smith, T., Hwang, P. H., Bhattacharyya, N., Lanier, B. J., Stambaugh, J. W., & Mugglin, A. S. (2011). Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. International Forum of Allergy and Rhinology, 1(1), 23-32. https://doi.org/10.1002/alr.20020

Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. / Murr, Andrew H.; Smith, Timothy; Hwang, Peter H.; Bhattacharyya, Neil; Lanier, Brent J.; Stambaugh, James W.; Mugglin, Andrew S.

In: International Forum of Allergy and Rhinology, Vol. 1, No. 1, 01.2011, p. 23-32.

Research output: Contribution to journalArticle

Murr, AH, Smith, T, Hwang, PH, Bhattacharyya, N, Lanier, BJ, Stambaugh, JW & Mugglin, AS 2011, 'Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent', International Forum of Allergy and Rhinology, vol. 1, no. 1, pp. 23-32. https://doi.org/10.1002/alr.20020
Murr, Andrew H. ; Smith, Timothy ; Hwang, Peter H. ; Bhattacharyya, Neil ; Lanier, Brent J. ; Stambaugh, James W. ; Mugglin, Andrew S. / Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. In: International Forum of Allergy and Rhinology. 2011 ; Vol. 1, No. 1. pp. 23-32.
@article{3b99f16f2dec4a9c845d8d98cd174f09,
title = "Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent",
abstract = "Background: Inflammation/polyp recurrence, adhesions, and middle turbinate lateralization are causes of suboptimal outcomes following sinus surgery and lead to increased rates of revision. A bioabsorbable, drug-eluting stent was evaluated for its ability to preserve sinus patency by providing controlled steroid delivery to the sinus mucosa. The study objective was to assess safety and efficacy of a steroid-eluting sinus stent when used following functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis (CRS). Methods: Prospective, multicenter, randomized, double-blind clinical trial, enrolling 43 patients in 2 groups. One group (n = 38) used an intrapatient control design comparing drug-eluting to non-drug-eluting stents. The other group (n = 5) received bilateral drug-eluting stents to assess systemic safety. Endoscopic follow-up was performed for 60 days. Efficacy endpoints included assessment of inflammation, polyp formation, adhesions, and middle turbinate position. Results: Stents were successfully deployed in all 86 sinuses. Compared to the control stent, the drug-eluting stent provided statistically significant reduction in inflammation at days 21 to 45 (p <0.003), frequency of polyp formation (p = 0.0391), and frequency of significant adhesion (p = 0.0313). Reduced frequency of middle turbinate lateralization was also apparent though not statistically significant. No device-related adverse events occurred. Eluted steroid was unquantifiable systemically and there was no evidence of adrenal cortical suppression. Conclusion: This study demonstrates the safety and efficacy of a novel bioabsorbable, steroid-eluting stent for use in CRS patients. The steroid-eluting stent is effective in improving wound healing by preserving sinus patency, reducing inflammation, and minimizing adhesions via controlled local steroid delivery without measurable systemic exposure.",
keywords = "Bioabsorbable, Corticosteroid, FESS, Functional endoscopic sinus surgery, Inflammation, Sinusitis, Stent, Steroid-eluting, Turbinate",
author = "Murr, {Andrew H.} and Timothy Smith and Hwang, {Peter H.} and Neil Bhattacharyya and Lanier, {Brent J.} and Stambaugh, {James W.} and Mugglin, {Andrew S.}",
year = "2011",
month = "1",
doi = "10.1002/alr.20020",
language = "English (US)",
volume = "1",
pages = "23--32",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent

AU - Murr, Andrew H.

AU - Smith, Timothy

AU - Hwang, Peter H.

AU - Bhattacharyya, Neil

AU - Lanier, Brent J.

AU - Stambaugh, James W.

AU - Mugglin, Andrew S.

PY - 2011/1

Y1 - 2011/1

N2 - Background: Inflammation/polyp recurrence, adhesions, and middle turbinate lateralization are causes of suboptimal outcomes following sinus surgery and lead to increased rates of revision. A bioabsorbable, drug-eluting stent was evaluated for its ability to preserve sinus patency by providing controlled steroid delivery to the sinus mucosa. The study objective was to assess safety and efficacy of a steroid-eluting sinus stent when used following functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis (CRS). Methods: Prospective, multicenter, randomized, double-blind clinical trial, enrolling 43 patients in 2 groups. One group (n = 38) used an intrapatient control design comparing drug-eluting to non-drug-eluting stents. The other group (n = 5) received bilateral drug-eluting stents to assess systemic safety. Endoscopic follow-up was performed for 60 days. Efficacy endpoints included assessment of inflammation, polyp formation, adhesions, and middle turbinate position. Results: Stents were successfully deployed in all 86 sinuses. Compared to the control stent, the drug-eluting stent provided statistically significant reduction in inflammation at days 21 to 45 (p <0.003), frequency of polyp formation (p = 0.0391), and frequency of significant adhesion (p = 0.0313). Reduced frequency of middle turbinate lateralization was also apparent though not statistically significant. No device-related adverse events occurred. Eluted steroid was unquantifiable systemically and there was no evidence of adrenal cortical suppression. Conclusion: This study demonstrates the safety and efficacy of a novel bioabsorbable, steroid-eluting stent for use in CRS patients. The steroid-eluting stent is effective in improving wound healing by preserving sinus patency, reducing inflammation, and minimizing adhesions via controlled local steroid delivery without measurable systemic exposure.

AB - Background: Inflammation/polyp recurrence, adhesions, and middle turbinate lateralization are causes of suboptimal outcomes following sinus surgery and lead to increased rates of revision. A bioabsorbable, drug-eluting stent was evaluated for its ability to preserve sinus patency by providing controlled steroid delivery to the sinus mucosa. The study objective was to assess safety and efficacy of a steroid-eluting sinus stent when used following functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis (CRS). Methods: Prospective, multicenter, randomized, double-blind clinical trial, enrolling 43 patients in 2 groups. One group (n = 38) used an intrapatient control design comparing drug-eluting to non-drug-eluting stents. The other group (n = 5) received bilateral drug-eluting stents to assess systemic safety. Endoscopic follow-up was performed for 60 days. Efficacy endpoints included assessment of inflammation, polyp formation, adhesions, and middle turbinate position. Results: Stents were successfully deployed in all 86 sinuses. Compared to the control stent, the drug-eluting stent provided statistically significant reduction in inflammation at days 21 to 45 (p <0.003), frequency of polyp formation (p = 0.0391), and frequency of significant adhesion (p = 0.0313). Reduced frequency of middle turbinate lateralization was also apparent though not statistically significant. No device-related adverse events occurred. Eluted steroid was unquantifiable systemically and there was no evidence of adrenal cortical suppression. Conclusion: This study demonstrates the safety and efficacy of a novel bioabsorbable, steroid-eluting stent for use in CRS patients. The steroid-eluting stent is effective in improving wound healing by preserving sinus patency, reducing inflammation, and minimizing adhesions via controlled local steroid delivery without measurable systemic exposure.

KW - Bioabsorbable

KW - Corticosteroid

KW - FESS

KW - Functional endoscopic sinus surgery

KW - Inflammation

KW - Sinusitis

KW - Stent

KW - Steroid-eluting

KW - Turbinate

UR - http://www.scopus.com/inward/record.url?scp=80055038293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055038293&partnerID=8YFLogxK

U2 - 10.1002/alr.20020

DO - 10.1002/alr.20020

M3 - Article

C2 - 22287304

AN - SCOPUS:80055038293

VL - 1

SP - 23

EP - 32

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 1

ER -